What if you decided to use K-sparing drugs (MRAs) to treat Heart Failure patients?

 

(K-sparing drugs = spironolactone & eplerenone)

Before and within 1 week of initiating therapy, two parameters must be assessed: serum potassium and creatinine clearance (or serum creatinine).

MRAs should not be initiated in patients with potassium concentrations greater than 5.0 mEq/L (5.0 mmol/L).

These agents should not be given when creatinine clearance is less than 30 mL/min (0.50 mL/s) or serum creatinine is greater than 2.5 mg/dL (221 μmol/L).